Treatment of renal carcinoma: a phase III randomized trial of oral medroxyprogesterone (Provera), hydroxyurea, and nafoxidine.
Seventy patients with metastatic renal carcinoma were randomized to receive hydroxyurea, nafoxidine, or medroxyprogesterone (Provera) orally. Sixty patients were considered evaluable, with a response rate of 5% for medroxyprogesterone (one complete remission) and hydroxyurea (one partial remission) and a response rate of 16% for nafoxidine (two complete remissions and one partial remission). Differences in response rates and duration of survival were not statistically significant. The major toxicity observed with hydroxyurea was hematologic, and the major toxic effect of nafoxidine was an ichthyosis-like skin rash. Toxicity for medroxyprogesterone was minimal.
D002986:Clinical Trials as Topic; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage* / Q000009:adverse effects; D007057:Ichthyosis / Q000139:chemically induced; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D017258:Medroxyprogesterone Acetate; D009256:Nafoxidine / Q000008:administration & dosage* / Q000009:adverse effects; D011379:Prognosis; D011759:Pyrrolidines / Q000008:administration & dosage*; D011897:Random Allocation; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced
D011759:Pyrrolidines; D009256:Nafoxidine; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone; D006918:Hydroxyurea